Green­Light's mR­NA vac­cine nabs tri­al OK; Ra­tio reels in ra­dio­ther­a­py funds

Green­Light Bio­sciences will test its Covid-19 mR­NA vac­cine in Rwan­da, the biotech said.

The RNA R&D and man­u­fac­tur­ing com­pa­ny said the Rwan­da FDA gave the go-ahead for a Phase I/II study test­ing the vac­cine as a boost­er for peo­ple who have al­ready been vac­ci­nat­ed against the pan­dem­ic virus.

“It is es­pe­cial­ly im­por­tant to de­vel­op vac­cines that are glob­al­ly af­ford­able and scal­able. Green­Light’s ef­forts to ini­ti­ate this clin­i­cal study in Rwan­da show the com­pa­ny’s com­mit­ment to sup­port Africa’s goal of af­ford­able vac­cine self-suf­fi­cien­cy,” said Mark Dy­bul, who chairs Green­Light’s sci­en­tif­ic ad­vi­so­ry board for hu­man health, in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER